Giuseppe
Emeritus
Influenza virus inactivation for studies of antigenicity and phenotypic neuraminidase inhibitor resistance profiling. (J Clin Microbiol., abstract, RA-1041, edited)
J Clin Microbiol. 2010 Jan 20. [Epub ahead of print]
Influenza virus inactivation for studies of antigenicity and phenotypic neuraminidase inhibitor resistance profiling.
Jonges M, Liu WM, van der Vries E, Jacobi R, Pronk I, Boog C, Koopmans M, Meijer A, Soethout E. - National Institute for Public Health and the Environment, Center for Infectious Disease Control, Laboratory for Infectious Diseases and Screening, Bilthoven, the Netherlands; Netherlands Vaccine Institute, Bilthoven, the Netherlands; Erasmus Medical Center, Department of Virology, Rotterdam, the Netherlands; Leiden University Medical Center, Department of Medical Microbiology, Leiden, the Netherlands; University Utrecht, Department of Immunology and Infectious Diseases, Utrecht, the Netherlands.
Introduction of a new influenza virus in humans urges to quickly analyze its virological and immunological characteristics to determine the impact on public health and to develop protective measures for the human population. At present, however, the necessity to execute pandemic influenza virus research at Biosafety Level 3 high containment conditions severely hampers timely characterization of these viruses. We tested heat, formalin, Triton X-100 and beta-propiolactone treatment for their potency to inactivate human influenza A(H3N2) and avian A(H7N3) virus, as well as seasonal and pandemic A(H1N1) virus isolates, while retaining their virological and immunological properties. Successful heat inactivation coincided with loss of haemagglutinin (HA) and neuraminidase (NA) characteristics, and beta-propiolactone inactivation reduced the HA-titer and NA activity of the human influenza virus 10-fold or more. Although Triton X-100 treatment resulted in inconsistent HA activity, the NA activity of culture supernatants was enhanced consistently. Nonetheless, formalin treatment best retained HA and NA properties. Triton X-100 treatment proved the easiest to use influenza virus inactivation protocol to be applied in combination with phenotypic NA inhibitor susceptibility assays, while formalin treatment preserved B-cell and T-cell epitope antigenicity allowing the detection of both humoral and cellular immune responses. In conclusion, we demonstrated successful influenza virus characterization using formalin and Triton X-100 inactivated virus. Application of these inactivation protocols limit work at BSL-3 conditions to virus culture, thus enabling more timely determination of public health impact and development of protective measures when a new influenza virus, e.g. pandemic A(H1N1)v, is introduced in humans.
PMID: 20089763 [PubMed - as supplied by publisher]
-
<cite cite="http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&dispmax=15&list_uids=20083824,20083823,20083142,20068058,20064360,20089763,20083672,20083661,20088690,20088689,20085957,20077593,20080801,20080770,20074687&dopt=AbstractPlus">15 selected items - PubMed result</cite>Influenza virus inactivation for studies of antigenicity and phenotypic neuraminidase inhibitor resistance profiling.
Jonges M, Liu WM, van der Vries E, Jacobi R, Pronk I, Boog C, Koopmans M, Meijer A, Soethout E. - National Institute for Public Health and the Environment, Center for Infectious Disease Control, Laboratory for Infectious Diseases and Screening, Bilthoven, the Netherlands; Netherlands Vaccine Institute, Bilthoven, the Netherlands; Erasmus Medical Center, Department of Virology, Rotterdam, the Netherlands; Leiden University Medical Center, Department of Medical Microbiology, Leiden, the Netherlands; University Utrecht, Department of Immunology and Infectious Diseases, Utrecht, the Netherlands.
Introduction of a new influenza virus in humans urges to quickly analyze its virological and immunological characteristics to determine the impact on public health and to develop protective measures for the human population. At present, however, the necessity to execute pandemic influenza virus research at Biosafety Level 3 high containment conditions severely hampers timely characterization of these viruses. We tested heat, formalin, Triton X-100 and beta-propiolactone treatment for their potency to inactivate human influenza A(H3N2) and avian A(H7N3) virus, as well as seasonal and pandemic A(H1N1) virus isolates, while retaining their virological and immunological properties. Successful heat inactivation coincided with loss of haemagglutinin (HA) and neuraminidase (NA) characteristics, and beta-propiolactone inactivation reduced the HA-titer and NA activity of the human influenza virus 10-fold or more. Although Triton X-100 treatment resulted in inconsistent HA activity, the NA activity of culture supernatants was enhanced consistently. Nonetheless, formalin treatment best retained HA and NA properties. Triton X-100 treatment proved the easiest to use influenza virus inactivation protocol to be applied in combination with phenotypic NA inhibitor susceptibility assays, while formalin treatment preserved B-cell and T-cell epitope antigenicity allowing the detection of both humoral and cellular immune responses. In conclusion, we demonstrated successful influenza virus characterization using formalin and Triton X-100 inactivated virus. Application of these inactivation protocols limit work at BSL-3 conditions to virus culture, thus enabling more timely determination of public health impact and development of protective measures when a new influenza virus, e.g. pandemic A(H1N1)v, is introduced in humans.
PMID: 20089763 [PubMed - as supplied by publisher]
-